Continuous PTH and PTHrP infusion causes suppression of bone formation and discordant effects on 1,25(OH)2 vitamin D

Journal of Bone and Mineral Research

Volumn 20, Issue 10, 2005, Pages 1792-1803

  Horwitz, Mara J ^a   Tedesco, Mary Beth ^a   Sereika, Susan M ^b   Syed, Mushtaq A ^a   Garcia Ocaña, Adolfo ^a   Bisello, Alessandro ^a   Hollis, Bruce W ^c   Rosen, Clifford J ^d   Wysolmerski, John J ^e   Dann, Pamela ^e   Gundberg, Caren ^e   Stewart, Andrew F ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d St Joseph's Hospital Bangor   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Humoral hypercalcemia of malignancy; Primary hyperparathyroidism; PTH; PTH related protein; Vitamin D

Indexed keywords

CALCIUM; PARATHYROID HORMONE; PARATHYROID HORMONE RELATED PROTEIN; PARATHYROID HORMONE[1-34]; PHOSPHORUS; VITAMIN D;

ADULT; ARTICLE; BONE MALFORMATION; CALCIUM BLOOD LEVEL; CONTINUOUS INFUSION; DOSE RESPONSE; FEMALE; HORMONE ACTION; HUMAN; HUMAN EXPERIMENT; HUMORAL HYPERCALCEMIA OF PREGNANCY; HYPERCALCEMIA; MALE; METABOLIC REGULATION; NORMAL HUMAN; OSSIFICATION; OSTEOBLAST; OSTEOLYSIS; PHOSPHATE BLOOD LEVEL; PRIMARY HYPERPARATHYROIDISM; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SYNTHESIS; VITAMIN BLOOD LEVEL; VITAMIN D METABOLISM;

ADULT; BONE DENSITY CONSERVATION AGENTS; CALCITRIOL; CALCIUM; FEMALE; HUMANS; HYPERCALCEMIA; MALE; OSTEOBLASTS; OSTEOGENESIS; PARATHYROID HORMONE-RELATED PROTEIN; TERIPARATIDE;

EID: 25444516518     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/JBMR.050602     Document Type: Article

References (61)

1. Bilezikian JP 2003 Primary hyperparathyroidism. In: Favus M (ed.) Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 5th ed. American Society for Bone and Mineral Research, Washington DC, USA, pp. 230-234.
2. Silverberg SJ, Bilezikian JP 2001 Primary hyperparathyroidism. In: DeGroot LJ, Jameson JL (eds.) Endocrinology. WB Saunders Co., Philadelphia, PA, USA, pp. 1075-1092.
3. Silverberg SJ, Bilezikian JP 2001 Primary hyperparathyroidism. In: Becker KL (ed.) Principles and Practice of Endocrinology and Metabolism, 3rd ed. Lippincott Williams and Wilkins, Philadelphia, PA, USA, pp. 564-574.
4. Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R 1993 Anabolic actions of parathyroid hormone on bone. Endocr Rev 14:690-709.
5. Dempster DW, Parisien M, Silverbrg SJ, Liang X-G, Schnitzer M, Shen V, Shane E, Kimmel DB, Lindsay R, Bilezikian JP 1999 On the mechanism of cancellous bone preservation in postmenopausal women with mild primary hyperparathyroidism. J Clin Endocrinol Metab 84:1562-1566.
6. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster J-Y, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH 2001 Effect of parathyroid hormone (1-34) on fractures and bone mineral density in post-menopausal women with osteoporosis. N Engl J Med 344:1434-1441.
7. Lindsay R, Nieves J, Formica C, Hennerman E, Woelfert L, Shen V, Dempster D, Cosman F 1997 Randomised clinical trial of the effect of parathyroid hormone on vertebral bone mass and fracture incidence among postmenopausal women with osteoporosis. Lancet 350:550-555.
8. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ 2003 The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207-1215.
9. Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM 2003 The effects of parathyroid hormone, alendronate or both in men with osteoporosis. N Engl J Med 349:1216-1226.
10. Khosla S 2003 Parathyroid hormone plus alendronate-a combination that does not add up. N Engl J Med 349:1277-1279.
11. Horwitz MJ, Stewart AF 2003 Humoral hypercalcemia of malignancy. In: Favus MF (ed.) Primer on Metabolic Bone Diseases and Disorders of Mineral Metabolism, 5th ed. American Society for Bone and Mineral Research, Washington DC, USA, pp. 246-250.
12. Stewart AF, Broadus AE 2001 Malignancy-associated hypercalcemia. In: DeGroot L, Jameson LJ (eds.) Endocrinology, 4th ed. W.B. Saunders, Philadelphia, PA, USA, pp. 1093-1100.
13. Stewart AF, Horst R, Deftos LJ, Cadman EC, Lang R, Broadus AE 1980 Biochemical evaluation of patients with cancer-associated hypercalcemia: Evidence for humoral and non-humoral groups. N Engl J Med 303:1377-1383.
14. Godsall JW, Burtis WJ, Insogna KL, Broadus AE, Stewart AF 1986 Nephrogenous cyclic AMP, adenylate cyclase-stimulating activity, and the humoral hypercalcemia of malignancy. Rec Prg Horm Res 40:705-750.
15. Stewart AF, Vignery A, Silvergate A, Ravin ND, LiVolsi V, Broadus AE, Baron R 1982 Quantitative bone histomorphometry in humoral hypercalcemia of malignancy: Uncoupling of bone cell activity. J Clin Endocrinol Metab 55:219-227.
16. Nakayama K, Fukumoto S, Takeda S, Takeuchi Y, Ishikawa T, Miura M, Hata K, Hane M, Tamura Y, Tanaka Y, Kitaoka M, Obara T, Ogata E, Matsumoto T 1996 Differences in bone and vitamin D metabolism between primary hyperparathyroidism and malignancy-associated hypercalcemia. J Clin Endocrinol Metab 81:607-611.
17. Ralston SH, Boyce BF, Cowan RA, Gardner MD, Fraser WD, Boyle IT 1989 Contrasting mechanisms of hypercalcemia in patients with early and advanced humoral hypercalcemia of malignancy. J Bone Miner Res. 4:103-111.
18. Horiuchi N, Caulfield MP, Fisher JE, Goldman ME, McKee RL, Reagan JE, Levy JJ, Nutt RF, Rodan SB, Schofield TL 1987 Similarity of synthetic peptide from human tumor to parathyroid hormone in vivo and in vitro. Science 238:1566-1568.
19. Walker AT, Stewart AF, Korn EA, Shiratori T, Mitnick MA, Carpenter TO 1990 Effect of parathyroid hormone-like peptides on 25-hydroxyvitamin D-1-α-hydroxylase activity in rodents. Am J Physiol 258:E297-E303.
20. 3 production. Endocrinology 124:2057-2062.
21. Plotkin H, Gundberg C, Mitnick M, Stewart AF 1998 Dissociation of bone formation from resorption during two-week treatment with hPTHrP(1-36) in humans: Potential as an anabolic therapy for osteoporosis. J Clin Endocrinol Metab 83:2786-2791.
22. Horwitz MJ, Tedesco MB, Gundberg C, Garcia-Ocaña A, Stewart AF 2003 Short-term, high-dose PTHrP as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 88:569-575.
23. Miao D, He B, Tong XK, Goltzman D, Karaplis AC 2002 Conditional knockout of PTHrP in osteoblasts leads to premature osteoporosis. J Bone Miner Res 17:1052.
24. Miao D, Li J, Xue Y, Su H, Karaplis AC, Goltzman D 2004 Parathyroid hormone-related peptide is required for increased trabecular bone volume in parathyroid hormone-null mice. Endocrinology 145:3554-3562.
25. Syed MA, Horwitz MJ, Tedesco MB, Garcia-Ocaña A, Wisniewski SR, Stewart AF 2001 Parathyroid hormone-related protein (1-36) stimulates renal tubular calcium reabsorption in normal human volunteers: Implications for the pathogenesis of humoral hypercalcemia of malignancy. J Clin Endocrinol Metab 86:1525-1531.
26. 2 vitamin D concentrations and fractional calcium excretion in healthy human volunteers. J Clin Endocrinol Metab 88:1603-1609.
27. Cosman F, Shen V, Fang X, Seibel M, Ratcliffe A, Lindsay R 1993 Estrogen protection against bone-resorbing effects of parathyroid hormone infusion: Assessment by use of biochemical markers. Ann Intern Med 118:337-343.
28. Cosman F, Morgan DC, Nieves JW, Shen V, Luckey MM, Dempster DW, Lindsay R, Parisien M 1997 Resistance to bone resorbing effects of PTH in black women. J Bone Miner Res 12:958-966.
29. Finkelstein JS, Schoenfeld DA 1999 Effects of gonadal suppression on the regulation of parathyroid hormone and 1,25-dihydroxyvitamin D secretion in women. J Clin Endocrinol Metab 84:2151-2156.
30. Leder BZ, Smith MR, Fallon MA 2001 Lee M-L T, Finkelstein JS. Effects of gonadal steroid suppression on skeletal sensitivity to parathyroid hormone in men. J Clin Endocrinol Metab 86:511-516.
31. Fraher LJ, Hodsman AB, Jonas K, Saunders D, Rose CI, Henderson JE, Hendy GN, Goltzman D 1992 A comparison of the in vivo biological responses to exogenous parathyroid hormone-(1-34) [PTH-(1-34)] and PTH-related peptide-(1-34) in man. J Clin Endocrinol Metab 75:417-423.
32. Stewart A, Mangin M, Wu T, Goumas D, Insogna KL, Burtis WJ, Broadus AE 1988 A synthetic human parathyroid hormone-like protein stimulates bone resorption and causes hypercalcemia in rats. J Clin Invest 81:596-600.
33. Everhart-Caye M, Inzucchi SE, Guinness-Henry J, Mitnick MA, Stewart AF 1996 Parathyroid hormone-related protein(1-36) is equipotent with parathyroid hormone(1-34) in humans. J Clin Endocrinol Metab 81:199-208.
34. Nakamoto C, Behar V, Chin K, Adams AE, Suva LJ, Rosenblatt M, Chorev M 1995 Probing the bimolecular interactions of parathyroid hormone with the human parathyroid hormone/parathyroid hormone-related protein receptor. 1. Design, synthesis and characterization of photoreactive benzophenone-containing analogs of parathyroid hormone. Biochemistry 34:10546-10552.
35. Henry JG, Mitnick MA, Dann PR, Stewart AF 1997 Parathyroid hormone-related protein(1-36) is biologically active when administered subcutaneously to humans. J Clin Endocrinol Metab 82:900-906.
36. Hollis BW, Kamerud JQ, Kurkowski A, Beaulieu J, Studley Napoli J 1996 Quantification of circulating 1,25(OH)2D by RIA with an 125-I-labled tracer. Clin Chem 42:586-592. B
37. Yang KH, dePapp AE, Soifer NS, Wu TL, Porter SE, Bellantoni M, Burtis WJ, Broadus AE, Philbrick WM, Stewart AF 1994 Parathyroid hormone-related protein: Evidence for transcript- and tissue-specific post-translational processing. Biochemistry 33:7460-7469.
38. Gundberg CM, Nieman SD, Abrams S, Rosen H 1998 Vitamin K status and bone health: An analysis of methods for the determination of " undercarboxylated" osteocalcin. J Clin Endocrinol Metab 83:3258-3266.
39. Rubin J, Ackert-Bicknell CL, Zhu L, Fan X, Murphy TC, Nanes MS, Marcus R, Holloway L, Beamer WG, Rosen CJ 2002 IGF-I regulates osteoprotegerin (OPG) and receptor activator of nuclear factor-kappa B ligand in vitro and OPG in vivo. J Clin Endocrinol Metab 87:4273-4279.
40. Bickle DD, Sakata T, Leary C, Elalieh H, Ginzinger D, Rosen CJ, Beamer W, Majumdar S, Halloran BP 2002 Insulin-like growth factor-1 is required for the anabolic actions of parathyroid hormone on rat bone. J Bone Miner Res 17:1570-1578.
41. Yakar S, Bouxsein ML, Glatt V, Gundberg CM, LeRoith D, Rosen CJ Circulating IGF-1 is essential for the anabolic effect of PTH on the skeleton. Program and Abstracts of the Annual Meeting of the Endocrine Society, New Orleans, LA, USA, June 2004.
42. Segre GV 1996 Receptors for parathyroid hormone and parathyroid hormone-related protein. In: Bilezikian JP, Raisz LG, Rodan GA (eds.) Principles of Bone Biology. Academic Press, San Diego, CA, USA, pp. 377-404.
43. Ahmed I, Gesty-Palmer D, Dresner MK, Luttrell LM 2003 Transactivation of the epidermal growth factor receptor mediates parathyroid hormone and prostaglandin F2α-stimulated mitogen-activated protein kinase activation in cultured transgenic murine osteoblasts. Mol Endocrinol 17:1607-1621.
44. Carpio L, Gladu J, Zoltzman D, Rabbani SA 2001 Induction of osteoblast differentiation indexes by PTHrP in MG-63 cells involves multiple signaling pathways. Am J Physiol Endocrinol Metab 281:E489-E499.
45. Sneddon WB, Liu F, Gesek FA, Friedman PA 2000 Obligate mitogen-activated protein kinase activation in parathyroid hormone stimulation of calcium transport but not calcium signaling. Endocrinology 141:485-493.
46. Guo J, Bringhurst FR, Kronenberg HM 2004 PTH receptor activates wnt/βcatenin signaling pathway in growth plate chondrocytes ex vivo. J Bone Miner Res 19:S1;S338.
47. Sneddon WB, Syme CA, Bisello A, Magyar CE, Rochdi MD, Parent J-L, Weinman EJ, Abou-Samra AB, Friedman PA 2003 Activation-independent parathyroid hormone receptor internalization is regulated by NHERF1 (EBP50). J Biol Chem 278:43787-43796.
48. Bonjour J-P, Phillipe J, Guelpa G, Bisetti A, Rizzoli R, Jung A, Rosini S, Kanis JA 1988 Bone and renal components in hypercalcemia of malignancy and response to a single infusion of clodronate. Bone 9:123-130.
49. VanHouten JN, Dann P, Stewart AF, Watson CJ, Pollack M, Karaplis AC, Wysolmerski JJ 2003 Mammary-specific deletion of parathyroid hormone-related protein preserves bone mass during lactation. J Clin Invest 112:1429-1436.
50. Samuels MH, Veldhuis J, Cawley C, Urban RJ, Luther M, Bauer R, Mundy GR 1993 Pulsatile secretion of PTH in normal young subjects: A deconvolution analysis. J Clin Endocrinol Metab 76:399-403.
51. Prank K, Nowlan SJ, Harms HM, Kloppstech M, Brabant G, Hesch R-D 1995 Time series prediction of parathyroid hormone concentration. J Clin Invest 95:2910-2919.
52. Harms HM, Schlinke E, Neubauer O, Kayser C, Wustermann PR, Horn R, Kulpmann W-R, von zur Muhlen A, Hesch R-D 1994 Pulse amplitude and frequency modulation of parathyroid hormone in primary hyperparathyroidism. J Clin Endocrinol Metab 78:53-57.
53. Plawner LL, Philbrick WM, Burtis WJ, Broadus AE, Stewart AF 1995 Secretion of parathyroid hormone-related protein: Cell-specific secretion via the regulated vs. the constitutive secretory pathway. J Biol Chem 270:14078-14084.
54. Ishizuye T, Yokose S, Hori M, Noda T, Suda T, Yoshiki S, Yamaguchi A 1997 Parathyroid hormone exerts disparate effects on osteoblastic differentiation depending on the exposure time in rat osteoblastic cells. J Clin Invest 99:2961-2970.
55. Ma YL, Cain RL, Halladay DL, Yang X, Zeng Q, Miles RR, Chandrasekhar S, Martin TJ, Onyia J 2001 Catabolic effects of continuous PTH(1-38) in vivo is associated with sustained stimulation of RANK-L and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology 142:4047-4054.
56. 2. Bone 11:61-65.
57. Dobnig H, Turner RT 1997 The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats. Endocrinology 138:4607-4612.
58. Linkhart TA, Mohan S 1989 Parathyroid hormone stimulates the release of insulin-like growth factor I (IGF-I), IGF-II from neonatal mouse calvariae in organ culture. Endocrinology 125:1484-1491.
59. McCarthy TL, Centrella M, Canalis E 1989 Parathyroid hormone enhances the transcript and polypeptide levels of insulin-like growth factor 1 in osteoblast enriched cultures from fetal rat bone. Endocrinology 124:1247-1253.
60. Rosen CJ 2000 Growth hormone and aging. Endocrine 12:197-201.
61. Burtis WJ, Brady TG, Orloff JJ, Ersbak JB, Warrell RP, Olson BR, Wu TL, Mitnick MA, Broadus AE, Stewart AF 1990 Immunochemical characterization of circulating parathyroid hormone-related protein in patients with humoral hypercalcemia of malignancy. N Engl J Med 322:1106-1112.